跳至主要内容

正大天晴启动IKZF1/3降解剂TQB3820临床研究

 近日,正大天晴公示启动《TQB3820片治疗恶性血液肿瘤的I期临床试验》(NCT05020639/CTR20211930),TQB3820可降解Aiolos和Ikaros。本试验目的为评估TQB3820片在复发或难治性多发性骨髓瘤、惰性B细胞非霍奇金淋巴瘤受试者中的安全性和耐受性。

临床试验申请:2021.4.19

临床试验公示:2021.8.5(CTR20211930)/2021.8.25(NCT05020639

根据专利检索结果可见正大天晴与明德新药联合申请CRBN蛋白相关疾病治疗药物的专利,这是否属于药明系国内新药研发服务的成果呢?

关于TQB3820

TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Modulation of Aiolos and Ikaros expression has the potential to correct multiple aspects of the immune dysregulation mediated by B cells.


附国内企业公开在研的分子胶降解剂:

康朴生物的IKZF1/3分子胶KPG-818;

诺诚健华的E3 ligase ICP-490;

标新生物分子胶GT919。

评论